These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35822422)

  • 1. The relationship between insulin and glucagon concentrations in non-diabetic humans.
    Laurenti MC; Arora P; Dalla Man C; Andrews JC; Rizza RA; Matveyenko A; Bailey KR; Cobelli C; Vella A
    Physiol Rep; 2022 Jul; 10(13):e15380. PubMed ID: 35822422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
    Greenbaum CJ; Prigeon RL; D'Alessio DA
    Diabetes; 2002 Apr; 51(4):951-7. PubMed ID: 11916912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of glucagon response on postprandial hyperglycemia in men with impaired glucose tolerance and type 2 diabetes mellitus.
    Henkel E; Menschikowski M; Koehler C; Leonhardt W; Hanefeld M
    Metabolism; 2005 Sep; 54(9):1168-73. PubMed ID: 16125528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.
    Abdul-Ghani M; DeFronzo RA
    J Clin Endocrinol Metab; 2007 May; 92(5):1778-84. PubMed ID: 17327375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus.
    Shah P; Vella A; Basu A; Basu R; Schwenk WF; Rizza RA
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4053-9. PubMed ID: 11095432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Examining the effects of hyperglycemia on pancreatic endocrine function in humans: evidence for in vivo glucotoxicity.
    Solomon TP; Knudsen SH; Karstoft K; Winding K; Holst JJ; Pedersen BK
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4682-91. PubMed ID: 23043193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes.
    Christensen MB; Calanna S; Holst JJ; Vilsbøll T; Knop FK
    J Clin Endocrinol Metab; 2014 Mar; 99(3):E418-26. PubMed ID: 24423311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of prediabetes: role of the liver in isolated fasting hyperglycemia and combined fasting and postprandial hyperglycemia.
    Basu R; Barosa C; Jones J; Dube S; Carter R; Basu A; Rizza RA
    J Clin Endocrinol Metab; 2013 Mar; 98(3):E409-17. PubMed ID: 23345093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and short-term administration of a sulfonylurea (gliclazide) increases pulsatile insulin secretion in type 2 diabetes.
    Juhl CB; Pørksen N; Pincus SM; Hansen AP; Veldhuis JD; Schmitz O
    Diabetes; 2001 Aug; 50(8):1778-84. PubMed ID: 11473038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired beta-cell and alpha-cell function in African-American children with type 2 diabetes mellitus--"Flatbush diabetes".
    Banerji MA
    J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():493-501. PubMed ID: 12017222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-mediated glucose disposal in insulin-resistant normoglycemic relatives of type 2 diabetic patients.
    Henriksen JE; Levin K; Thye-Rønn P; Alford F; Hother-Nielsen O; Holst JJ; Beck-Nielsen H
    Diabetes; 2000 Jul; 49(7):1209-18. PubMed ID: 10909980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the role of the gut in diabetic hyperglucagonaemia.
    Lund A
    Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients.
    Kruszynska YT; Goulas S; Wollen N; McIntyre N
    J Hepatol; 1998 Feb; 28(2):280-91. PubMed ID: 9514541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
    Heise T; Mari A; DeVries JH; Urva S; Li J; Pratt EJ; Coskun T; Thomas MK; Mather KJ; Haupt A; Milicevic Z
    Lancet Diabetes Endocrinol; 2022 Jun; 10(6):418-429. PubMed ID: 35468322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic physiologic hyperglycemia impairs insulin-mediated suppression of plasma glucagon concentration in healthy humans.
    Chen X; Merovci A; DeFronzo RA; Tripathy D
    Metabolism; 2023 May; 142():155512. PubMed ID: 36746320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes.
    Juhl CB; Hollingdal M; Sturis J; Jakobsen G; Agersø H; Veldhuis J; Pørksen N; Schmitz O
    Diabetes; 2002 Feb; 51(2):424-9. PubMed ID: 11812750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.